ARCTURUS THERAPEUTICS HOLDINGS INC. Diluted Shares Outstanding (Weighted Average)
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Diluted Shares Outstanding (Weighted Average) of 28.42 million shares for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-06-30 was 28.42M shares, a 4.77% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for the quarter ending 2026-03-31 was 28.42M shares, a 4.85% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-12-31 was 28.12M shares, a 3.79% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for the quarter ending 2025-09-30 was 27.19M shares, a 0.47% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for fiscal 2025 was 27.39M shares, a 1.43% increase from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for fiscal 2024 was 27.00M shares, a 1.40% increase from fiscal 2023.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for fiscal 2023 was 26.63M shares, a 1.72% decline from fiscal 2022.
- ARCTURUS THERAPEUTICS HOLDINGS INC. weighted average number of shares outstanding, diluted for fiscal 2022 was 27.09M shares, a 2.95% increase from fiscal 2021.
| Period end | Weighted Average Number of Shares Outstanding, Diluted 3 month | Weighted Average Number of Shares Outstanding, Diluted 3 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 6 month | Weighted Average Number of Shares Outstanding, Diluted 6 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 9 month | Weighted Average Number of Shares Outstanding, Diluted 9 month as first filed | Weighted Average Number of Shares Outstanding, Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 28.42M shares 10-Q · filed 2026-08-06 | 28.42M shares 10-Q · filed 2026-08-06 | 28.32M shares derived: average of 3 quarters · filed 2026-08-06 | 28.04M shares derived: average of 4 quarters · filed 2026-08-06 | |||
| 2026-03-31 | 28.42M shares 10-Q · filed 2026-05-07 | 28.27M shares derived: average of 2 quarters · filed 2026-05-07 | 27.91M shares derived: average of 3 quarters · filed 2026-05-07 | 27.71M shares derived: average of 4 quarters · filed 2026-08-06 | |||
| 2025-12-31 | 28.12M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 27.65M shares derived: average of 2 quarters · filed 2026-03-03 | 27.48M shares derived: average of 3 quarters · filed 2026-08-06 | 27.39M shares 10-K · filed 2026-03-03 | |||
| 2025-09-30 | 27.19M shares 10-Q · filed 2025-11-12 | 27.16M shares derived: average of 2 quarters · filed 2026-08-06 | 27.14M shares 10-Q · filed 2025-11-12 | 27.13M shares derived: average of 4 quarters · filed 2026-08-06 | |||
| 2025-06-30 | 27.13M shares 10-Q · filed 2026-08-06 | 27.12M shares 10-Q · filed 2026-08-06 | 27.11M shares derived: average of 3 quarters · filed 2026-08-06 | 27.10M shares derived: average of 4 quarters · filed 2026-08-06 | |||
| 2025-03-31 | 27.11M shares 10-Q · filed 2026-05-07 | 27.10M shares derived: average of 2 quarters · filed 2026-05-07 | 27.09M shares derived: average of 3 quarters · filed 2026-05-07 | 27.06M shares derived: average of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | 27.09M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 27.08M shares derived: average of 2 quarters · filed 2026-03-03 | 27.04M shares derived: average of 3 quarters · filed 2026-03-03 | 27.00M shares 10-K · filed 2026-03-03 | |||
| 2024-09-30 | 27.06M shares 10-Q · filed 2025-11-12 | 27.01M shares derived: average of 2 quarters · filed 2025-11-12 | 26.97M shares 10-Q · filed 2025-11-12 | 26.94M shares derived: average of 4 quarters · filed 2026-03-03 | |||
| 2024-06-30 | 26.97M shares 10-Q · filed 2025-08-11 | 26.92M shares 10-Q · filed 2025-08-11 | 26.89M shares derived: average of 3 quarters · filed 2026-03-03 | 26.81M shares derived: average of 4 quarters · filed 2026-03-03 | |||
| 2024-03-31 | 26.88M shares 10-Q · filed 2025-05-12 | 26.86M shares derived: average of 2 quarters · filed 2026-03-03 | 26.76M shares derived: average of 3 quarters · filed 2026-03-03 | 26.71M shares derived: average of 4 quarters · filed 2026-03-03 | |||
| 2023-12-31 | 26.84M shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 26.70M shares derived: average of 2 quarters · filed 2026-03-03 | 26.66M shares derived: average of 3 quarters · filed 2026-03-03 | 26.63M shares 10-K · filed 2026-03-03 | |||
| 2023-09-30 | 26.57M shares 10-Q · filed 2024-11-07 | 26.57K shares 10-Q · filed 2023-11-14 | 26.57M shares derived: average of 2 quarters · filed 2024-11-07 | 26.56M shares 10-Q · filed 2024-11-07 | 26.56K shares 10-Q · filed 2023-11-14 | 47.14M shares derived: average of 4 quarters · filed 2025-03-06 | |
| 2023-06-30 | 26.56M shares 10-Q · filed 2024-08-05 | 26.56K shares 10-Q · filed 2023-08-07 | 26.56M shares 10-Q · filed 2024-08-05 | 26.56K shares 10-Q · filed 2023-08-07 | 54.00M shares derived: average of 3 quarters · filed 2025-03-06 | 40.51M shares derived: average of 4 quarters · filed 2025-03-06 | |
| 2023-03-31 | 27.15M shares 10-Q · filed 2024-05-08 | 27.15K shares 10-Q · filed 2023-05-09 | 67.72M shares derived: average of 2 quarters · filed 2025-03-06 | 45.16M shares derived: average of 3 quarters · filed 2025-03-06 | 33.87M shares derived: average of 4 quarters · filed 2025-03-06 | ||
| 2022-12-31 | 108.29M shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | 54.16M shares derived: average of 2 quarters · filed 2025-03-06 | 36.12M shares derived: average of 3 quarters · filed 2025-03-06 | 27.09M shares 10-K · filed 2025-03-06 | |||
| 2022-09-30 | 26.47K shares 10-Q · filed 2023-11-14 | 26.47M shares 10-Q · filed 2022-11-09 | 26.45K shares derived: average of 2 quarters · filed 2023-11-14 | 26.42K shares 10-Q · filed 2023-11-14 | 26.42M shares 10-Q · filed 2022-11-09 | 6.61M shares derived: average of 4 quarters · filed 2024-03-14 | |
| 2022-06-30 | 26.43K shares 10-Q · filed 2023-08-07 | 26.43M shares 10-Q · filed 2022-08-09 | 26.40K shares 10-Q · filed 2023-08-07 | 26.40M shares 10-Q · filed 2022-08-09 | 8.80M shares derived: average of 3 quarters · filed 2024-03-14 | 13.19M shares derived: average of 4 quarters · filed 2024-03-14 | |
| 2022-03-31 | 26.38K shares 10-Q · filed 2023-05-09 | 13.19M shares derived: average of 2 quarters · filed 2024-03-14 | 17.58M shares derived: average of 3 quarters · filed 2024-03-14 | 19.76M shares derived: average of 4 quarters · filed 2024-03-14 | |||
| 2021-12-31 | 26.36M shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | 26.35M shares derived: average of 2 quarters · filed 2024-03-14 | 26.34M shares derived: average of 3 quarters · filed 2024-03-14 | 26.32M shares 10-K · filed 2024-03-14 | |||
| 2021-09-30 | 26.34M shares 10-Q · filed 2022-11-09 | 26.33M shares derived: average of 2 quarters · filed 2022-11-09 | 26.30M shares 10-Q · filed 2022-11-09 | ||||
| 2021-06-30 | 26.32M shares 10-Q · filed 2022-08-09 | 26.28M shares 10-Q · filed 2022-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |